Harvard University still holds a patent for any animal genetically engineered to develop cancer after an appeal against its patent broke up without conclusion last week. Some anti-patent campaigners now predict that Harvard will emerge from the appeal with a restricted patent, for an "onco-rodent".
The appeal was held by the European patent office after objections to Harvard's patent from campaigners across Europe. The appeal will continue in writing.